Treatments in Endocrinology

, Volume 2, Issue 5, pp 321–330 | Cite as

Hormonal Contraception in Women with Diabetes Mellitus

Special Considerations
  • Jill ShaweEmail author
  • Ross Lawrenson
Therapy In Practice


Contraception is an important issue for women with diabetes mellitus as unplanned pregnancy can present major maternal and perinatal complications. The rising incidence of diabetes worldwide means increasing thought needs to be given to contraceptive options for these women. This article reviews current evidence and recommends best practice for prescribing hormonal contraceptives in women with diabetes.

Women with diabetes have the same choice of contraceptives as the general population, but the potential metabolic effects of hormonal methods need to be considered in relation to an individual’s diabetic profile and their need for effective contraception. Currently, there appear to be wide variations in the way that professionals evaluate the risk-benefit equation, and significant differences in prescribing practice have been identified. The World Health Organization (WHO) has established medical eligibility criteria to assist in assessing such risks.

Cardiovascular disease is a major concern, and for women with diabetes who have macrovascular or microvascular complications, nonhormonal methods are recommended. Studies of young women with diabetes and no vascular changes who are taking low-dose combined oral contraceptives (COCs) have been reassuring, although larger long-term studies are needed. There is little evidence that any changes in glycemic control caused by COCs are of clinical relevance. While low-dose COCs appear to cause minimal change in the lipid profile and may even be beneficial in this respect, there are some concerns in relation to progestogen only pills and injectable contraceptives in certain women.

There is little evidence of best practice for the follow-up of women with diabetes prescribed hormonal contraception. It is generally agreed that blood pressure, weight, and body mass index measurements should be ascertained, and blood glucose levels and baseline lipid profiles assessed as relevant. Research on hormonal contraception has been carried out in healthy populations; more studies are needed in women with diabetes and women who have increased risks of cardiovascular disease.


Glycemic Control Diabetic Retinopathy Retinal Vein Occlusion Ethinylestradiol Diabetic Woman 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    WHO Study Group on Prevention of Diabetes Mellitus Prevention of diabetes mellitus: report of a WHO study group. WHO Technical Report Series 844. Geneva: WHO, 1994Google Scholar
  2. 2.
    Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14: S7–S85CrossRefGoogle Scholar
  3. 3.
    WHO. Improving access to quality care in Family Planning medical eligibility criteria for contraceptive use. WHO 2000 [online]. Available from URL: [Accessed 2002 Oct 16]Google Scholar
  4. 4.
    ONS. Key Health Statistics from General Practice 1998. London: ONS, 2000Google Scholar
  5. 5.
    ACOG Committee on Practice Bulletins — Gynecology. ACOG practice bulletin: the use of hormonal contraception in women with coexisting medical conditions. Int J Gynaecol Obstet 2001; 75(1): 93–106CrossRefGoogle Scholar
  6. 6.
    Betschart J. Oral contraception and adolescent women with insulin-dependent diabetes mellitus: risks, benefits, and implications for practice. Diabetes Educ 1996; 22(4): 374–8PubMedCrossRefGoogle Scholar
  7. 7.
    Girling J, de Swiet M, Hope C. Contraception for women with diabetes or hypertension. Trends Urol Gynaecol Sexual Health 1997 Nov/Dec; 2(8): 23–34Google Scholar
  8. 8.
    Mills J, Knowpp R, Simpson J. Lack or relation of increased malformation rates in infants of diabetic mothers to glycaemic control during organogenesis. N Engl J Med 1988; 318: 671–6PubMedCrossRefGoogle Scholar
  9. 9.
    Mestman JH, Schmidt Sarosi C. Diabetes mellitus and fertility control: contraception management issues. Am J Obstet Gynecol 1993; 168: 2012–20PubMedGoogle Scholar
  10. 10.
    Kjaer K, Hagen C, Sando SH, et al. Contraception in women with IDDM: an epidemiological study. Diabetes Care 1992; 15: 1585–90PubMedCrossRefGoogle Scholar
  11. 11.
    Hollingworth BA. Contraception and medical disorders. In: Kubba A, Sanfillippo J, Hampton N, editors. Contraception and office gynaecology. London: WB Saunders, 1999: 193–208Google Scholar
  12. 12.
    Klein BEK, Klein R, Moss SE. Exogenous estrogen exposures and changes in diabetic retinopathy. Diabetes Care 1999; 22(12): 1984–7PubMedCrossRefGoogle Scholar
  13. 13.
    Laing SP, Swerdlow AJ, Slater SD, et al. The British Diabetic Association Cohort Study, 11: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999; 16(6): 466–71PubMedCrossRefGoogle Scholar
  14. 14.
    Swerdlow AJ, Jones ME. Mortality during 25 years of follow-up of a cohort with diabetes. Int J Epidemiol 1996; 25: 1250–61PubMedCrossRefGoogle Scholar
  15. 15.
    Fontbonne A, Basdevant A, Faguer B, et al. Contraceptive practice in 209 diabetic women regularly attending a specialized diabetes clinic. Diabete Metab 1987; 13(4): 411–6PubMedGoogle Scholar
  16. 16.
    Kimmerle R, Schmitt G, Berger M. Contraception in patients with type I diabetes: a survey of 808 women of reproductive age. Geburtshilfe Frauenheilkd 1994; 54(12): 691–6PubMedCrossRefGoogle Scholar
  17. 17.
    International Planned Parenthood Federation (PPF). Directory of hormonal contraceptives [online]. Available from URL: [Accessed 2003 Jan 7]Google Scholar
  18. 18.
    Crook D. Do different brands of oral contraception differ in their effects on cardiovascular disease? Br J Obstet Gynaecol 1997; 104: 516–20PubMedCrossRefGoogle Scholar
  19. 19.
    Porcile A, Gallardo E. Long term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives. Fertil Steril 1991; 55: 877–81PubMedGoogle Scholar
  20. 20.
    Parsey KS, Pong A. An open label multicenter study to evaluate Yasmin, a low dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000; 61(2): 105–11PubMedCrossRefGoogle Scholar
  21. 21.
    British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF) 2003 Mar; 45Google Scholar
  22. 22.
    Wingrave SJ, Kay CR, Vessey MP. Oral contraceptives & diabetes mellitus. BMJ 1979; 1(6155): 23PubMedCrossRefGoogle Scholar
  23. 23.
    Kjos SL, Peters RK, Xiang A, et al. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 1998; 280(6): 533–8PubMedCrossRefGoogle Scholar
  24. 24.
    Kim C, Scidel KW, Begier EA, et al. Diabetes and depot medroxyprogesterone contraception in Navajo women. Arch Intern Med 2001; 161(14): 1766–71PubMedCrossRefGoogle Scholar
  25. 25.
    Chasan-Taber L, Willett WC, Stampfer MJ, et al. A prospective study of oral contraceptives and NIDDM among US women. Diabetes Care 1997; 20(3): 330–5PubMedCrossRefGoogle Scholar
  26. 26.
    Kim C, Siscovick DS, Sidney S, et al. Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women: the CARDIA study. Diabetes Care 2002; 25(6): 1027–32PubMedCrossRefGoogle Scholar
  27. 27.
    Lawrenson RA, Leydon GM, Williams TJ, et al. Patterns of contraception in UK women with Type 1 diabetes: a GP database study. Diabet Med 1999; 16: 395–9PubMedCrossRefGoogle Scholar
  28. 28.
    Gibb D, Hockey S, Brown LJ, et al. Attitudes and knowledge regarding contraception and pre-pregnancy counseling in insulin dependent diabetes. N Z Med J 1994; 107: 484–6PubMedGoogle Scholar
  29. 29.
    RCOG. Royal College of General Practitioners oral contraceptive study. Lancet 1977; II: 727–31Google Scholar
  30. 30.
    Vessey MP, McPherson K, Johnson B. Mortality among women participating in the Oxford Family Planning Association Contraceptive Study. Lancet 1977; II: 731–7CrossRefGoogle Scholar
  31. 31.
    Jensen G, Nyboe J, Appleyard M, et al. Risk factors for acute myocardial infarction in Copenhagen: II. smoking, alcohol intake, physical activity, obesity, oral contraception, diabetes, lipids, and blood pressure. Eur Heart J 1991; 12(3): 298–308PubMedGoogle Scholar
  32. 32.
    Sidney S, Siscovick DS, Petitti DB, et al. Myocardial infarction & use of low-dose oral contraceptives, a pooled analysis of 2 US studies. Circulation 1998; 98: 1058–63PubMedCrossRefGoogle Scholar
  33. 33.
    Farley TM, Collins J, Schlesselman JJ. Hormonal contraception and risk of cardiovascular disease: an international perspective. Contraception 1998; 57(3): 211–30PubMedCrossRefGoogle Scholar
  34. 34.
    Lidegaard O. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol 1995; 102(2): 153–9PubMedCrossRefGoogle Scholar
  35. 35.
    Mammen EF. Oral contraceptives and blood coagulation: a critical review. Am J Obstet Gynecol 1982 Mar 15; 142 (6 Pt 2): 781–90PubMedGoogle Scholar
  36. 36.
    Petersen KR, Skouby SO, Sidelmann J, et al. Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus. Am J Obstet Gynecol 1994; 171: 400–5PubMedGoogle Scholar
  37. 37.
    Diab KM, Zaki MM. Contraception in diabetic women: comparative metabolic study of Norplant, depot medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A. J Obstet Gynaecol Res 2000; 26(1): 17–26PubMedCrossRefGoogle Scholar
  38. 38.
    Sorensen MB, Collins P, Ong PJL, et al. Long term use of contraceptive Depot medroxyprogesterone Acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 2002; 106(13): 1646–51PubMedCrossRefGoogle Scholar
  39. 39.
    Monster TB, Janssen WM, de Jong PE, et al. Prevention of Renal and Vascular End Stage Disease Study Group. Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med 2001; 161(16): 2000–5PubMedCrossRefGoogle Scholar
  40. 40.
    Garg SK, Chase P, Marshall G, et al. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA 1994; 271(14): 1099–102PubMedCrossRefGoogle Scholar
  41. 41.
    Kirwan JF, Tsaloumas H, Prior P, et al. Sex hormone preparations and retinal vein occlusion. Eye 1997; 11(1): 53–6PubMedCrossRefGoogle Scholar
  42. 42.
    Amiel SA, Caprio S, Sherwin RS, et al. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 1991; 72: 277–82PubMedCrossRefGoogle Scholar
  43. 43.
    Polderman KH, Gooren LJG, Asscheman H, et al. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994; 79: 265–71PubMedCrossRefGoogle Scholar
  44. 44.
    Anderson B, Mattson L-A, Hahn L, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 638–43CrossRefGoogle Scholar
  45. 45.
    Darko DA, Dornhorst A, Kennedy G, et al. Glycaemic control and plasma lipoproteins in menopausal women with type 2 diabetes treated with oral and transdermal combined hormone replacement therapy. Diabet Res Clin Pract 2001; 54(3): 157–64CrossRefGoogle Scholar
  46. 46.
    Livingstone C, Collison M. Sex steroids and insulin resistance. Clin Sci (Lond) 2002; 102(2): 151–66CrossRefGoogle Scholar
  47. 47.
    Skouby SO, Molsted-Pedersen L, Petersen KR. Contraception for women with diabetes: an update. Baillieres Clin Obstet Gynaecol 1991; 5: 493–503PubMedCrossRefGoogle Scholar
  48. 48.
    Blum M, Rusecky Y, Gelernter I. Glycohemoglobin (Hb A1) levels in oral contraceptive users. Eur J Obstet Gynecol Reprod Biol 1983; 15(2): 97–101PubMedCrossRefGoogle Scholar
  49. 49.
    Steel JM, Duncan LJ. Contraception for the insulin-dependent diabetic woman: the view from one clinic. Diabetes Care 1980; 3(4): 557–60PubMedCrossRefGoogle Scholar
  50. 50.
    Radberg T, Gustafson A, Skryten A, et al. Oral contraception in diabetic women: a cross-over study on serum and HDL lipids and diabetes control during progestogen and combined estrogen/progestogen contraception. Horm Metab Res 1982; 14(2): 61–5PubMedCrossRefGoogle Scholar
  51. 51.
    Skouby SO, Molsted-Pedersen L, Kuhl C. Low dosage oral contraception in women with previous gestational diabetes. Obstet Gynecol 1982; 59(3): 325–8PubMedGoogle Scholar
  52. 52.
    Godsland IF. Interaction of oral contraceptive use with the effects of age, exercise habits and other cardiovascular risk modifiers on metabolic risk markers. Contraception 1996; 53(1): 9–16PubMedCrossRefGoogle Scholar
  53. 53.
    Klein B, Moss SE, Klein R. Oral contraceptives in women with diabetes. Diabetes Care 1990; 13(8): 1585–90CrossRefGoogle Scholar
  54. 54.
    Kjaer K, Hagen C, Sando S, et al. Contraception in women with IDDM. Diabetes Care 1992; 15(11): 1585–90PubMedCrossRefGoogle Scholar
  55. 55.
    Petersen KR, Skouby SO, Vedel P, et al. Hormonal contraception in women with IDDM. Diabetes Care 1995; 18(6): 800–6PubMedCrossRefGoogle Scholar
  56. 56.
    Dorflinger LJ. Metabolic effects of implantable steroid contraceptives for women. Contraception 2002; 65(1): 47–62PubMedCrossRefGoogle Scholar
  57. 57.
    Geurts TBP, Goorissen EM, Sitsen JMA. Summary of drug interactions with oral contraceptives. Carnforth: The Parthenon Publishing Group, 1993Google Scholar
  58. 58.
    Steel JM. Pregnancy counseling and contraception in the insulin-dependent diabetic patient. Clin Obstet Gynaecol 1985; 28(3): 553–66CrossRefGoogle Scholar
  59. 59.
    Selby PL, Oakley CE. Women’s problems and diabetes. Diabet Med 1992; 9(3): 290–2PubMedCrossRefGoogle Scholar
  60. 60.
    World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case control study. Lancet 1995; 346: 1575–82Google Scholar
  61. 61.
    Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet 1995; 346: 1589–93PubMedCrossRefGoogle Scholar
  62. 62.
    Spitzer WO, Lewis MA, Heinemann LA, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312: 83–8PubMedCrossRefGoogle Scholar
  63. 63.
    Farmer RD, Lawrenson RA, Todd JC, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 2000; 49(6): 580–90PubMedCrossRefGoogle Scholar
  64. 64.
    Lewis MA, MacRae KD, Kuhl-Habichl D, et al. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999; 14(6): 1493–9PubMedCrossRefGoogle Scholar
  65. 65.
    Mr Justice MacKay. XYZ and others & Schering Healthcare Ltd, Organon Laboratories Ltd and John Wyeth and Brother Ltd. High Court of Justice, Queens Bench Division, London. 29th July 2002, EWHC 1420 (QB)Google Scholar
  66. 66.
    RCOG Faculty of Family Planning & Reproductive Health Care. First prescription of combined oral contraception: recommendations for clinical practice. Br J Fam Planning 2000; 26(1): 27–38Google Scholar
  67. 67.
    Manolopoulos K, Kiess W, Braems GA, et al. Which contraceptive methods are recommended for young women with type 1 diabetes mellitus? A survey among gynaecologists in Greece. Eur J Obstet Gynaecol Reprod Biol 2001; 99(2): 232–7CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Post Graduate Medical SchoolUniversity of SurreySurrey Research ParkUK

Personalised recommendations